<DOC>
	<DOCNO>NCT02947464</DOCNO>
	<brief_summary>Cure rate o pediatric Obstructive Sleep Apnea Syndrome ( OSAS ) gold-standard-treatment adenotonsillectomy 50-80 % . Treatment alternative scarce , poorly effective base low scientific evidence . This mean one five patient remain exposed well-known neurocognitive , behavioral quality live adverse effect disease . Rapid Maxillary Expansion , orthopaedic-orthodontic treatment pediatric malocclusion , recently show promising result treatment pediatric OSAS base upon effect craniofacial upper airway growth , usually limited patient . The investigator propose randomize , prospective , controlled trial patient Pediatric OSAS non-responding adenotonsillectomy . The aim study enhance treatment success rate avoid morbimortality associate disease persistence childhood development adult life .</brief_summary>
	<brief_title>Rapid Maxillary Expansi√≥n Residual Pediatric Obstructive Sleep Apnea After Adenotonsillectomy</brief_title>
	<detailed_description />
	<mesh_term>Apnea</mesh_term>
	<mesh_term>Sleep Apnea Syndromes</mesh_term>
	<mesh_term>Sleep Apnea , Obstructive</mesh_term>
	<criteria>Children ( boys girl ) 4 9 year age . Residual OSAS adenotonsillectomy ( described Apnea Hypopnea Index 5.6 objectively measure mean Home Respiratory Polygraphy ) . Rapid Maxillary expansion indication . Parents tutor sign Informed Consent . Craniofacial syndromes neurologic disease diagnosis . Adenoid residual hypertrophy occlude &gt; 50 % nasal airway measure mean nasal flexible fiberoptic endoscopy tonsillar residual hypertrophy &gt; 2 measure direct intraoral physical exam . Residual severe pediatric OSAS comorbidities urge CPAP treatment initiation .</criteria>
	<gender>All</gender>
	<minimum_age>4 Years</minimum_age>
	<maximum_age>9 Years</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>